Mapping of the Wnt/β-Catenin/TCF Response Elements in the Human Versican Promoter

  • Maziar Rahmani
  • Jon M. Carthy
  • Bruce M. McManusEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 836)


Versican, a chondroitin sulfate proteoglycan, is one of the main components of the extracellular matrix and is considered to be crucial to several key cellular processes involved in development and disease. There is differential temporal and spatial expression of versican by multiple cell types and in different developmental and pathological timeframes. In order to fully appreciate the functional roles of versican as it relates to changing patterns of expression in development and disease, an in-depth knowledge of versican’s biosynthetic processing is necessary. We have recently shown that β-catenin/T-cell factor (TCF) complex formation at the versican promoter site is essential for activation of versican transcription. The transcriptional activator β-catenin is the key mediator of the canonical Wnt signaling pathway. However, β-catenin does not itself bind DNA and thus functions via interaction with TCF/Lymphoid-enhancing factor (LEF) transcription factors. These proteins contain a high-mobility group (HMG) box that binds DNA in a sequence-specific manner. Thus, in the case of active Wnt signaling, β-catenin activates, in cooperation with proteins of the TCF/LEF family, the expression of a wide variety of target genes. The goal of this chapter is to describe the techniques used to elucidate the transcriptional control of versican by the β-catenin/TCF response elements in its promoter site and to demonstrate how this signaling may be assayed experimentally. These approaches provide insight into the transcriptional regulation of the versican gene and provide the basis for the identification of novel Wnt/β-catenin/TCF-regulated genes that are part of the signaling machinery regulating early embryogenesis, neoplasia, and cardiovascular remodeling.

Key words

Versican Wnt pathway β-catenin TCF/LEF recognition site Luciferase Promoter activity EMSA 



This work was supported in part by a Grant-in-Aid from the Heart and Stroke Foundation of British Columbia and Yukon.


  1. 1.
    Kinsella, M.G., Bressler, S.L., and Wight, T.N. (2004) The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. Crit Rev Eukaryot Gene Expr. 14, 203–234.PubMedCrossRefGoogle Scholar
  2. 2.
    Rahmani, M., Wong, B.W., Ang, L., Cheung, C.C., Carthy, J.M., Walinski, H., and McManus, B.M. (2006) Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol. 84, 77–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Wight, T.N. and Merrilees, M.J. (2004) Proteo-glycans in atherosclerosis and restenosis: key roles for versican. Circ Res. 94, 1158–1167.PubMedCrossRefGoogle Scholar
  4. 4.
    Rahmani, M., McDonald, P.C., Wong, B.W., and McManus, B.M. (2004) Transplant vascular disease: Role of lipids and proteoglycans. Can J Cardiol. 20: 58B–65B.PubMedGoogle Scholar
  5. 5.
    Wight, T.N. (2008) Arterial remodeling in vascular disease: a key role for hyaluronan and versican. Front Biosci. 13, 4933–4937.PubMedCrossRefGoogle Scholar
  6. 6.
    Ricciardelli, C., Sakko, A.J., Ween, M.P., Russell, D.L., and Horsfall, D.J. (2009) The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev. 28, 233–245.PubMedCrossRefGoogle Scholar
  7. 7.
    Morgenstern, D.A., Asher, R.A., and Fawcett, J.W. (2002) Chondroitin sulphate proteoglycans in the CNS injury response. Prog Brain Res. 137, 313–332.PubMedCrossRefGoogle Scholar
  8. 8.
    Zimmermann, D.R. and Dours-Zimmermann, M.T. (2008) Extracellular matrix of the central nervous system: from neglect to challenge. Histochem Cell Biol. 130, 635–653.PubMedCrossRefGoogle Scholar
  9. 9.
    Wu, Y.J., Lapierre, D., Wu, J., Yee, A.J., and Yang, B.B. (2005) The interaction of versican with its binding partners. Cell Res. 15, 483–494.PubMedCrossRefGoogle Scholar
  10. 10.
    Cowin, P. (1994) Unraveling the cytoplasmic interactions of the cadherin superfamily. Proc Natl Acad Sci USA 91, 10759–10761.PubMedCrossRefGoogle Scholar
  11. 11.
    Korinek, V., Barker, N., Morin, P.J., van Wichen, D., de Weger, R., Kinzler, K.W., et al. (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science 275, 1784–1787.PubMedCrossRefGoogle Scholar
  12. 12.
    Rahmani, M., Read, J.T., Carthy, J.M., McDonald, P.C., Wong, B.W., Esfandiarei, M., et al. (2005) Regulation of the versican promoter by the beta-catenin-T-cell factor complex in vascular smooth muscle cells. J Biol Chem. 280, 13019–13028.PubMedCrossRefGoogle Scholar
  13. 13.
    Read, J.T., Rahmani, M., Boroomand, S., Allahverdian, S., McManus, B.M., and Rennie, P.S. (2007) Androgen receptor regulation of the versican gene through an androgen response element in the proximal promoter. J Biol Chem. 282, 31954–31963.PubMedCrossRefGoogle Scholar
  14. 14.
    Farb, A., Kolodgie, F.D., Hwang, J.Y., Burke, A.P, Tefera, K., Weber, D.K., et al. (2004) Extracellular matrix changes in stented human coronary arteries. Circulation 110, 940–947.PubMedCrossRefGoogle Scholar
  15. 15.
    Lin, H., Ignatescu, M., Wilson, J.E., Roberts, C.R., Horley, K.J., Winters, G.L., et al. (1996) Prominence of apolipoproteins B, (a), and E in the intimae of coronary arteries in transplanted human hearts: geographic relationship to vessel wall proteoglycans. J Heart Lung Transplant. 15, 1223–1232.PubMedGoogle Scholar
  16. 16.
    Lin, H., Wilson, J.E., Roberts, C.R., Horley, K.J., Winters, G.L., Costanzo, M.R., and McManus, B.M. (1996) Biglycan, decorin, and versican protein expression patterns in coronary arteriopathy of human cardiac allograft: distinctness as compared to native atherosclerosis. J Heart Lung Transplant. 15, 1233–1247.PubMedGoogle Scholar
  17. 17.
    Lin, H., Kanda, T., Hoshino, Y., Takase, S., Kobayashi, I., Nagai, R., and McManus, B.M. (1998) Versican, biglycan and decorin protein expression patterns in coronary arteries: Analysis of primary and restenotic lesions. Cardiovasc Pathol. 7, 31–37.CrossRefGoogle Scholar
  18. 18.
    Williams, K.J. and Tabas, I. (1995) The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 15, 551–561.PubMedCrossRefGoogle Scholar
  19. 19.
    Williams, K.J. (2001) Arterial wall chondroitin sulfate proteoglycans: diverse molecules with distinct roles in lipoprotein retention and atherogenesis. Curr Opin Lipidol. 12, 477–487.PubMedCrossRefGoogle Scholar
  20. 20.
    Naso, M.F., Zimmermann, D.R., and Iozzo, R.V. (1994) Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter. J Biol Chem; 269, 32999–33008.PubMedGoogle Scholar
  21. 21.
    Yeung, L.H., Read, J.T., Sorenson, P., Nelson, C.C., Gleave, M., Jia, W., and Rennie, P.S. (2003) Identification and characterization of a prostate-specific androgen independentprotein binding site in the probasin promoter. Biochem J. 371, 843–855.PubMedCrossRefGoogle Scholar
  22. 22.
    Thyberg, J. (1996) Differentiated properties and proliferation of arterial smooth muscle cells in culture. Int Rev Cytol. 169, 183–265.PubMedCrossRefGoogle Scholar
  23. 23.
    Campbell, J.H. and Campbell, G.R. (1993) Culture techniques and their applications to studies of vascular smooth muscle. Clin Sci (Lond) 85, 501–513.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Maziar Rahmani
    • 1
  • Jon M. Carthy
    • 1
  • Bruce M. McManus
    • 1
    Email author
  1. 1.Department of Pathology and Laboratory Medicine, The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, Institute for Heart + Lung HealthUniversity of British ColumbiaVancouverCanada

Personalised recommendations